Microbiological Research
journal homepage: www.elsevier.com/locate/micres
Review
Marine Biotechnology Laboratory, Department of Chemistry, Pukyong National University, Busan 608-737, Republic of Korea
Marine Bioprocess Research Center, Pukyong National University, Busan 608-737, Republic of Korea
c
Centre of Advanced Study in Marine Biology, Faculty of Marine Sciences, Annamalai University, Parangipettai 608 502, Tamil Nadu, India
b
a r t i c l e
i n f o
Article history:
Received 4 May 2013
Received in revised form 29 June 2013
Accepted 22 July 2013
Available online 16 August 2013
Keywords:
Marine actinobacteria
Antibiotics
Bioactive compounds
Secondary metabolites
a b s t r a c t
Marine actinobacteria are one of the most efcient groups of secondary metabolite producers and are very
important from an industrial point of view. Many representatives of the order Actinomycetales are prolic producers of thousands of biologically active secondary metabolites. Actinobacteria from terrestrial
sources have been studied and screened since the 1950s, for many important antibiotics, anticancer, antitumor and immunosuppressive agents. However, frequent rediscovery of the same compounds from the
terrestrial actinobacteria has made them less attractive for screening programs in the recent years. At the
same time, actinobacteria isolated from the marine environment have currently received considerable
attention due to the structural diversity and unique biological activities of their secondary metabolites.
They are efcient producers of new secondary metabolites that show a range of biological activities
including antibacterial, antifungal, anticancer, antitumor, cytotoxic, cytostatic, anti-inammatory, antiparasitic, anti-malaria, antiviral, antioxidant, anti-angiogenesis, etc. In this review, an evaluation is made
on the current status of research on marine actinobacteria yielding pharmaceutically active secondary
metabolites. Bioactive compounds from marine actinobacteria possess distinct chemical structures that
may form the basis for synthesis of new drugs that could be used to combat resistant pathogens. With the
increasing advancement in science and technology, there would be a greater demand for new bioactive
compounds synthesized by actinobacteria from various marine sources in future.
2013 Elsevier GmbH. All rights reserved.
Contents
1.
2.
3.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Marine actinobacteria as a novel source of bioactive compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Secondary metabolites from marine actinobacteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.
Antibacterial activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.2.
Antifungal activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.
Anticancer activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.4.
Antitumor activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.5.
Cytotoxic activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.6.
Cytostatic activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.7.
Anti-inammatory activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.8.
Anti-parasitic activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.9.
Anti-malarial activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.10.
Antiviral activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.11.
Antioxidant activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.12.
Anti-angiogenesis activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
263
263
265
265
267
268
269
270
272
273
273
274
274
275
275
4.
263
1. Introduction
New drugs, especially antibiotics, are urgently needed to
counter and reverse the spread of antibiotic resistant pathogens
(Payne et al. 2006; Talbot et al. 2006) and to combat life-threatening
diseases such as cancer (Olano et al. 2009). Although considerable
progress is being made within the elds of chemical synthesis and
engineered biosynthesis of antimicrobial compounds, nature still
remains the richest and the most versatile source for new antibiotics (Koehn and Carter 2005; Baltz 2006; Pelez 2006).
Actinobacteria, which are the prolic producers of antibiotics and important suppliers to the pharmaceutical industry, can
produce a wide variety of secondary metabolites (Baltz 2005).
Actinobacteria belonging to the family Actinomycetaceae are well
known for their ability to produce secondary metabolites many of
which are active against pathogenic microorganisms. Traditionally, these bacteria have been isolated from terrestrial sources,
although the rst report of mycelium-forming actinobacterium
from the marine sediments appeared several decades ago (Weyland
1969). It is only more recently that marine actinobacteria have
become recognized as a source of novel antibiotics and anticancer agents with unusual structures and properties (Jensen et al.
2005).
Marine actinobacteria are the best sources of secondary metabolites and the vast majority of these compounds are derived from the
single genus Streptomyces, whose species are distributed widely
in the marine and terrestrial habitats (Pathom-Aree et al. 2006a)
and are of commercial interest due to their unique capacity
to produce novel metabolites. It was also perceived that Streptomyces species will have a cosmopolitan distribution, as they
produce abundant spores that are readily dispersed (Antony-Babu
et al. 2008) and these lamentous bacteria are well adapted to
the marine environment and can break down complex biological polymers (Anderson and Wellington 2001). In fact, the genus
Streptomyces alone accounts for a remarkable 80% of the actinobacterial natural products reported to date, a biosynthetic capacity
that remains without rival in the microbial world (Watve et al.
2001).
Marine actinobacteria are widely distributed in biological
sources such as shes, molluscs, sponges, seaweeds, mangroves,
besides seawater and sediments. These organisms are gaining
importance not only for their taxonomic and ecological perspectives, but also for their production of novel bioactive compounds
like antibiotics, antitumor agents, immunosuppressive agents,
enzymes, enzyme inhibitors, pigments (Dharmaraj 2010). In this
review we focuses on novel bioactive compounds identied from
marine actinobacteria and classied them in terms of their chemical structure, covering the literature to date.
2. Marine actinobacteria as a novel source of bioactive
compounds
Marine actinobacteria are the most economically and biotechnologically priceless prokaryotes. Representative genera of
actinobacteria include Streptomyces, Actinomyces, Arthrobacter,
Corynebacterium, Frankia, Micrococcus, Micromonospora and several
others. Secondary metabolites produced by the marine actinobacteria possess a wide range of biological activities (Oldeld et al.
1998; Mann 2001; Berdy 2005; Manivasagan et al. 2013). The
genus Streptomyces alone produces a large number of bioactive
264
Table 1
Novel secondary metabolites produced by marine actinobacteria.
Compound
Species
Other biological
activity
Reference
Antibacterial activity
Abyssomicins
Bonactin
Chloro-dihydroquinones
Diazepinomicin
Verrucosispora sp.
Streptomyces sp.
Streptomyces sp.
Micromonosproa sp.
Antifungal
Anticancer
Anticancer;
anti-inammatory
Cytotoxic
Cytotoxic
Antifungal; anticancer
Frigocyclinone
Essramycin
Lynamicins
Marinopyrroles
Caboxamycin
Himalomycins
Marinomycins
Glyciapyrroles
Tirandamycin
Bisanthraquinone
Gutingimycin
Helquinoline
Lajollamycin
TP-1161
Lincomycin
Tirandamycins
1,4-Dihydroxy-2-(3-hydroxybutyl)-9,10anthraquinone
9,10-anthrac
Antifungal activity
Chandrananimycin
Streptomyces griseus
Streptomyces sp.
Marinispora sp.
Streptomyces sp.
Streptomyces sp.
Streptomyces sp.
Marinispora
Streptomyces sp.
Streptomyces sp.
Streptomyces sp.
Streptomyces sp.
Janibacter limosus
Streptomyces nodosus
Nocardiopsis sp.
Streptomyces lincolnensis
Streptomyces sp.
Streptomyces sp.
N-(2-hydroxyphenyl)-2-phenazinamine (NHP)
Anticancer activity
Salinosporamide A
Caprolactones
3,6-Disubstituted indoles
IB-00208
1-Hydroxy-1-norresistomycin
Nocardia dassonvillei.
Antialgal;
antibacterial;
anticancer
Anticancer
Salinispora tropica
Streptomyces sp.
Streptomyces sp.
Actinomadura sp.
Streptomyces chinaensis
Antibacterial
ZHD-0501
Antitumor activity
Chinikomycins
Glyciapyrroles
Mechercharmycin A
Aureoverticillactam
Arenicolides
Chalcomycin
Daryamides
Aureolic acid
1,8-Dihydroxy-2-ethyl-3-methylanthraquinone
Arenimycin
Mitomycin C
Staurosporinone
Streptokordin
Elaiomycins B and C
Cytotoxic activity
Manumycins
Salinipyrones
Pacicanones
Actinofuranones
Nonactin
Resistoavine
Neomarinones
Piericidins
Lucentamycins
Arenamides
Piperazimycins
Mansouramycin C
Usabamycins
Pyridinium
ML-449 (macrolactam)
Salinosporamide B & C
Albidopyrone
Actinomadura sp.
Streptomyces sp.
Streptomyces sp.
Thermoactinomyces sp
Streptomyces aureoverticillatus
Salinispora arenicola
Streptomyces sp.
Streptomyces sp.
Streptomyces sp.
Streptomyces sp.
Salinispora arenicola
Streptomyces lavendulae
Streptomyces sp.
Streptomyces sp.
Streptomyces sp.
Antibacterial;
Phycotoxicity
Li et al. (2005)
Macherla et al. (2005)
Kanoh et al. (2005)
Mitchell et al. (2004)
Williams et al. (2007)
Wu et al. (2007)
Asolkar et al. (2006)
Lu et al. (2012)
Huang et al. (2006)
Asolkar et al. (2006)
Mao et al. (1999)
Wu et al. (2006)
Jeong et al. (2006)
Helaly et al. (2011)
Streptomyces sp.
Salinispora pacica
Salinispora pacica
Streptomyces
Streptomyces sp.
Streptomyces chibaensis
Actinomycetales
Streptomyces sp.
Nocardiopsis lucentensis
Salinipora arenicola
Streptomyces sp.
Streptomyces sp.
Streptomyces sp.
Amycolatopsis alba.
Streptomyces sp.
Salinipora tropica
Streptomyces sp.
Antimicrobial
Cytotoxic (inhibitor of
proteintyrosine
phosphatise)
Actinomadura sp.
265
Table 1 (Continued )
Compound
Cytostatic activity
Proximicins
Anti-inammatory activity
Cyclomarins
Salinamides A and B
Anti-parasitic activity
Avermectins
Anti-malarial activity
Trioxacarcin
Anti viral activity
Benzastatin C
Antioxidant activity
Dermacozines A-G
Lipocarbazoles
2-Allyloxyphenol
Anti-angiogenesis activity
Streptopyrrolidine
Cyclo-(l-Pro-l-Met)
Species
Other biological
activity
Reference
Verrucosispora sp.
Streptomyces sp.
Salinispora
Arenicola
Streptomyces sp.
Streptomyces avermitilis
Streptomyces sp.
Antibacterial;
antitumor
Streptomyces nitrosporeus
Dermacoccus
Tsukamurella pseudospumae
Streptomyces sp.
Antitumor;
Antiprotozoal
Antimicrobial
Streptomyces sp.
Nocardiopsis sp.
266
Fig. 1. Flow chart depicting the main techniques of isolation and culture of marine actinobacteria, extraction of compound and its chemical and biological characterization
leading to the development of a pharmaceutical product.
267
Fig. 2. Chemical structure of Abyssomicin C, Bonactin, Chlorinated dihydroquinones, Diazepinomicin, Frigocyclinone and Essramycin.
268
Fig. 4. Chemical structure of Glyciapyrroles A, Glyciapyrroles B, Glyciapyrroles C, Tirandamycin C, Bisanthraquinone and Chandrananimycin A.
Fig. 5. Chemical structure of N-(2-hydroxyphenyl)-2-phenazinamine (NHP), Salinosporamide A, Caprolactones, Chinikomycin A, Marinomycins and Aureoverticillactam.
an orally active proteasome inhibitor that induces apoptosis in multiple myeloma cells with mechanisms distinct from the commercial
proteasome inhibitor anticancer drug Bortezomib (Chauhan et al.
2005). It is being developed by Nereus Pharmaceuticals, Inc. (as NPI0052) and was scheduled to enter clinical studies for treatment of
cancer in humans in 2006. NPI-0052 is currently being evaluated
in multiple phase I trials for solid tumors, lymphoma and multiple myeloma (http://www.nereuspharm.com/NPI-0052.shtml).
NPI-0052 represents the rst clinical candidate for the treatment
of cancer produced by saline fermentation of an obligate marine
actinobacterium (Fenical et al. 2009).
Prudhomme et al. (2008) tested Salinosporamide A for its utility as an anticancer and antimalarial drug. It was shown to have
inhibitory activity against parasite development in vitro (Plasmodium falciparum) and in vivo (Plasmodium yoelii). The exact mode by
which salinosporamide A inhibits Plasmodium erythrocytic development is unknown; however, it is likely due to the inhibition of
the proteasome complex. It is interesting to note that chloroquine
resistant strains are still sensitive to Salinosporamide A. Targeting
the proteasome system has a huge therapeutic implication as it can
restrain growth and survival of most cell types (Prudhomme et al.
2008). These attributes, taken with the fact that it is already in phase
I clinical trials as an antitumor agent, make it an excellent candidate for alternative therapies, such as antibacterial, anti-parasitic,
antifungal or antiviral treatments. Caprolactones (20) (Fig. 5) are
new antibiotics isolated from Streptomyces sp. showing moderate
phytotoxicity and promising activity against cancer cells with concomitant low general cytotoxicity (Stritzke et al. 2004).
3.4. Antitumor activity
Thousands of antibiotics have been successfully applied to prevent and treat diseases caused by microbes in the clinical settings
over the past half-century. It is therefore no wonder that more
and more tumor cells and bacteria have developed antimicrobial
resistance or even multidrug-resistance. In the past, solution to
the problem depended primarily on the development of novel
antineoplastic and antimicrobial agents from common resources.
A great number of structurally interesting and biologically active
secondary metabolites produced by microorganisms have been
reported; many of which being exploited by the pharmaceutical industry as potent antibiotics (Bernan et al. 2004; Berdy
269
270
Fig. 7. Chemical structure of Daryamide B and C, Manumycin A, Aureolic acid and Salinipyrones A.
271
Fig. 8. Chemical structure of Salinipyrones B, Pacicanones A, Pacicanones B, Actinofuranone A, Actinofuranone B, Nonactin, Resistoavine and Neomarinones.
272
Fig. 9. Chemical structure of Piericidin, Lucentamycin A, Lucentamycin B, Lucentamycin C, Lucentamycin D and Arenamides A.
Fig. 10. Chemical structure of Piperazimycin, Mansouramycin C, Usabamycins, Pyridinium and Albidopyrone.
273
and C (51) (Fig. 11) exhibit weak antibacterial activity but have
a strong cytostatic effect against various human tumor cell lines.
Proximicins A, B and C showed signicant growth inhibitory activity against human gastric adenocarcinoma AGS (GI50 of 0.6, 1.5
and 0.25 M, respectively) and hepatocellular carcinoma Hep G2
(GI50 of 0.82, 9.5 and 0.78 M, respectively) (Fiedler et al. 2008;
Schneider et al. 2008), and were found to induce the arrest of AGS
cells in G0/G1 and to increase the levels of p53 and p21 (Schneider
et al. 2008).
274
communities that utilize the coastal waters for recreational activities and for food industries (e.g. sh, shellsh), as well as to those
regions of the country, such as Hawaii, where the loss of these
marine resources would have a devastating effect on the lifestyle
and economy of the people and (2) chemotherapy of viral diseases
of humans and lower animals.
To be of practical use, it is imperative that marine antiviral
agents are to be isolated from pure cultures, identied and characterized. Their spectrum and mechanism of antiviral activity should
also be clearly established. Their active principle(s) and moieties
should be identied and chemically characterized in order to facilitate application of biotechnological methods for increased yields
and cost effective production.
Currently, it appears that there have been only a few compounds
derived from marine actinobacteria with antiviral activity. Benzastatin C (56) (Fig. 12), a 3-chloro-tetrahydroquinolone alkaloid
obtained from Streptomyces nitrosporeus, showed antiviral activity in a dose-dependant manner with EC50 values of 1.92, 0.53,
and 1.99 g/mL against herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and vesicular stomatitis virus
(VSV), respectively (Lee et al. 2007). Kumar et al. (2006) reported
the antiviral property of a marine Streptomyces against White Spot
Syndrome Virus (WSSV) in penaeid shrimps. WSSV infection can
cause cumulative mortality up to 100% within 310 days, thereby
causing considerable economic loss to the shrimp farmers. In this
context, antibiotic extracts were obtained from the fermentation
broth of twenty-ve isolates of marine Streptomyces (isolated from
the coastal waters of Southwest coast of India), incorporated into
the formulated feeds and supplemented to the post-larvae (PL-20)
of the black tiger shrimp Penaeus monodon for 2 weeks and challenged with WSSV. The pattern of post-challenge survival % (PCS %)
in the 27 treatments (25 experimental and two controls) exhibited
a wide range of variation from 11 to 83% during the course of the
experiment. PCS % was lowest in the controls (C1-4.3%, C2-5.2%) on
day 7. However, six probiotic feeds (SA 2, SA 8, SL 27, SL 33, SL 39,
and SL 85) supplemented to postlarval shrimp recorded the highest
PCS %, ranging between 50 and 83%. Also, severity of the infection
275
276
277
Lee J-G, Yoo I-D, Kim W-G. Differential antiviral activity of benzastatin C and
its dechlorinated derivative from Streptomyces nitrosporeus. Biol Pharm Bull
2007;30(4):7957.
Li F, Maskey RP, Qin S, Sattler I, Fiebig HH, Maier A, et al. Chinikomycins A and B:
Isolation, structure elucidation, and biological activity of novel antibiotics from
a marine Streptomyces sp. isolate M045. J Nat Prod 2005;68(3):34953.
Lin C-C, Lin H-L. Remediation of soil contaminated with the heavy metal (Cd2+ ). J
Hazard Mater 2005;122(1):715.
Lopes MS, de Souza Pietra RC, Borgati TF, Romeiro CF, Jnior PA, Romanha AJ, et al.
Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds. Eur J Med Chem 2011;46(11):54437.
Lpez JMS, Insua MM, Baz JP, Puentes JLF, Hernndez LMC. New cytotoxic indolic
metabolites from a marine Streptomyces. J Nat Prod 2003;66(6):8634.
Lu J, Ma Y, Liang J, Xing Y, Xi T, Lu Y. Aureolic acids from a marine-derived Streptomyces sp. WBF16. Microbiol Res 2012;167:5905.
Macherla VR, Liu J, Bellows C, Teisan S, Nicholson B, Lam KS, et al. Glaciapyrroles A, B,
and C, pyrrolosesquiterpenes from a Streptomyces sp. isolated from an Alaskan
marine sediment. J Nat Prod 2005;68(5):7803.
Manam RR, Teisan S, White DJ, Nishino T, Grodberg J, Neuteboom STC, et al. Lajollamycin, a nitro-tetraene spiro-b-lactone-g-lactam antibiotic from the marine
actinomycete Streptomyces nodosus. J Nat Prod 2005;68:2403.
Manivasagan P, Venkatesan J, Sivakumar K, Kim S-K. Marine actinobacterial metabolites: current status and future perspectives. Microbiol Res 2013;168:31132.
Mann J. Natural products as immunosuppressive agents. Nat Prod Rep
2001;18(4):41730.
Mao Y, Varoglu M, Sherman DH. Molecular characterization and analysis of the
biosynthetic gene cluster for the antitumor antibiotic mitomycin C from Streptomyces lavendulae NRRL 2564. Chem Biol 1999;6(4):25163.
Maskey RP, Helmke E, Laatsch H. Himalomycin A and B: isolation and structure elucidation of new fridamycin type antibiotics from a marine Streptomyces isolate.
J Antibiot 2003a;56(11):9429.
Maskey RP, Li F, Qin S, Fiebig HH, Laatsch H. Chandrananimycins A approximately C:
production of novel anticancer antibiotics from a marine Actinomadura sp. isolate M048 by variation of medium composition and growth conditions. J Antibiot
2003b;56(7):62234.
Maskey RP, Sevvana M, Usn I, Helmke E, Laatsch H. Gutingimycin: a highly
complex metabolite from a marine streptomycete. Angew Chem Int Ed
2004a;43(10):12813.
Maskey RP, Helmke E, Kayser O, Fiebig HH, Maier A, Busche A, et al. Anti-cancer
and antibacterial trioxacarcins with high anti-malaria activity from a marine
Streptomycete and their absolute stereochemistry. J Antibiot 2004b;57(12):
7719.
Mayer A, Rodrguez AD, Berlinck RG, Hamann MT. Marine pharmacology in 2003-4:
marine compounds with anthelmintic antibacterial, anticoagulant, antifungal,
anti-inammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis,
and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol
Part C: Toxicol Pharmacol 2007;145(4):55381.
McArthur KA, Mitchell SS, Tsueng G, Rheingold A, White DJ, Grodberg J, et al.
Lynamicins A-E, chlorinated bisindole pyrrole antibiotics from a novel marine
actinomycete. J Nat Prod 2008;71(10):17327.
Melisi D, Chiao PJ. NF-B as a target for cancer therapy. Expert Opin Therap Targets
2007;11(2):13344.
Mikami Y. Biological work on medically important Nocardia species. Actinomycetologica 2007;21(1):4651.
Miller ED, Kauffman CA, Jensen PR, Fenical W. Piperazimycins: cytotoxic hexadepsipeptides from a marine-derived bacterium of the genus Streptomyces. J Org
Chem 2007;72(2):32330.
Mincer TJ, Fenical W, Jensen PR. Culture-dependent and culture-independent diversity within the obligate marine actinomycete genus Salinispora. Appl Environ
Microbiol 2005;71(11):701928.
Mitchell SS, Nicholson B, Teisan S, Lam KS, Barbara C. Aureoverticillactam, a novel
22-atom macrocyclic lactam from the marine actinomycete Streptomyces aureoverticillatus. J Nat Prod 2004;67(8):14002.
Moore BS, Trischman JA, Seng D, Kho D, Jensen PR, Fenical W. Salinamides,
antiinammatory depsipeptides from a marine streptomycete. J Org Chem
1999;64(4):114550.
Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004;430(6996):2429.
Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deciency in the developing mouse lens. Nature 1994;371:724.
Oh D-C, Gontang EA, Kauffman CA, Jensen PR, Fenical W. Salinipyrones and
pacicanones, mixed-precursor polyketides from the marine actinomycete
Salinispora pacica. J Nat Prod 2008;71(4):5705.
Okami Y, Hotta K. Search and discovery of new antibiotics. Good fellow. In: Williams
M, Mordarski STM, editors. Actinomycetes in biotechnology. New york: Academic Press Inc.; 1988. p. 3367.
Olano C, Mndez C, Salas JA. Antitumor compounds from marine actinomycetes. Mar
Drugs 2009;7(2):21048.
Oldeld C, Wood NT, Gilbert SC, Murray FD, Faure FR. Desulphurisation of benzothiophene and dibenzothiophene by actinomycete organisms belonging to the
genus Rhodococcus, and related taxa. Antonie Van Leeuwenhoek 1998;74(1):
11932.
Pathirana C, Jensen PR, Fenical W. Marinone and debromomarinone: antibiotic
sesquiterpenoid naphthoquinones of a new structure class from a marine bacterium. Tetrahedron Lett 1992;33(50):76636.
278
Pathom-Aree W, Stach JEM, Ward AC, Horikoshi K, Bull AT, Goodfellow M. Diversity
of actinomycetes isolated from Challenger Deep sediment (10, 898 m) from the
Mariana Trench. Extremophiles 2006a;10:1819.
Pathom-Aree W, Nogi Y, Ward AC, Horikoshi K, Bull AT, Goodfellow M. Dermacoccus barathri sp. nov. and Dermacoccus profundi sp. nov., novel actinomycetes
isolated from deep-sea mud of the Mariana Trench. Int J Syst Evol Microbiol
2006b;56(10):23037.
Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the
challenges of antibacterial discovery. Nat Rev Drug Discovery 2006;6(1):2940.
Pelez F. The historical delivery of antibiotics from microbial natural productscan
history repeat? Biochem Pharmacol 2006;71(7):98190.
Peschke U, Schmidt H, Zhang HZ, Piepersberg W. Molecular characterization of
the lincomycin-production gene cluster of Streptomyces lincolnensis 78-11. Mol
Microbiol 2006;16(6):113756.
Pimentel-Elardo SM, Kozytska S, Bugni TS, Ireland CM, Moll H, Hentschel U. Antiparasitic compounds from Streptomyces sp. strains isolated from Mediterranean
sponges. Mar Drugs 2010;8(2):37380.
Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, et al.
Trends in infectious diseases mortality in the United States. J Am Med Assoc
1996;275(3):18993.
Prudhomme J, McDaniel E, Ponts N, Bertani S, Fenical W, Jensen P, et al. Marine
actinomycetes: a new source of compounds against the human malaria parasite.
PLoS ONE 2008;3(6):e2335.
Rabea EI, Badawy ME-T, Stevens CV, Smagghe G, Steurbaut W. Chitosan as
antimicrobial agent: applications and mode of action. Biomacromolecules
2003;4(6):145765.
Rath J-P, Kinast S, Maier ME. Synthesis of the fully functionalized core structure of
the antibiotic abyssomicin C. Org Lett 2005;7(14):308992.
Ravikumar S, Fredimoses M, Gnanadesigan M. Anticancer property of sediment actinomycetes against MCF-7 and MDA-MB-231 cell lines. Asian Pacic J Tropical
Biomed 2012a;2(2):926.
Ravikumar S, Gnanadesigan M, Thajuddin N, Chakkaravarthi V, Banerjee B. Anticancer property of sponge associated actinomycetes along Palk Strait. J Pharm
Res 2010a;3(10):24157.
Ravikumar S, Thajuddin N, Suganthi P, Jacob Inbaneson S, Vinodkumar T. Bioactive
potential of seagrass bacteria against human bacterial pathogens. J Environ Biol
2010b;31(3):3879.
Ravikumar S, Gnanadesigan M, Saravanan A, Monisha N, Brindha V, Muthumari
S. Antagonistic properties of seagrass associated Streptomyces sp., RAUACT1: a source for anthraquinone rich compound. Asian Pacic J Tropical Med
2012b;5(11):88790.
Renner MK, Shen Y-C, Cheng X-C, Jensen PR, Frankmoelle W, Kauffman CA, et al. new
antiinammatory cyclic peptides produced by a marine bacterium (Streptomyces
sp.). J Am Chem Soc 1999;121(49):112736.
Reynolds JM, El Bissati K, Brandenburg J, Gnzl A, Mamoun CB. Antimalarial activity
of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B. BMC
Clin Pharmacol 2007;7(1):713.
Reynolds L, Killilea S, Redmer D. Angiogenesis in the female reproductive system.
FASEB J 1992;6(3):88692.
Riedlinger J, Reicke A, Zhner H, Krismer B, Bull AT, Maldonado LA, et al.
Abyssomicins, inhibitors of the para-aminobenzoic acid pathway produced by
the marine Verrucosispora strain AB-18-032. J Antibiot 2004;57(4):2719.
Risau W. Mechanisms of angiogenesis. Nature 1997;386(6626):6714.
Rodriguez JC, Fernandez PIL, Perez BJ, Canedo LM. IB-00208, a new cytotoxic
polycyclic xanthone produced by a marine-derived Actinomadura II. Isolation, physico-chemical properties and structure determination. J Antibiot
2003;56(3):31821.
Salomon CE, Magarvey NA, Sherman DH. Merging the potential of microbial genetics with biological and chemical diversity: an even brighter future for marine
natural product drug discovery. Nat Prod Rep 2004;21(1):10521.
Sato S, Iwata F, Yamada S, Kawahara H, Katayama M. Usabamycins AC: new
anthramycin-type analogues from a marine-derived actinomycete. Bioorg Med
Chem Lett 2011;21(23):7099101.
Sattler I, Thiericke R, Zeeck A. The manumycin-group metabolites. Nat Prod Rep
1998;15(3):22140.
Schneider K, Nachtigall J, Ha nchen A, Nicholson G, Goodfellow M, Su ssmuth RD,
et al. Lipocarbazoles, secondary metabolites from Tsukamurella pseudospumae
Acta 1857 with antioxidative activity. J Nat Prod 2009;72(10):176872.
Schneider K, Keller S, Wolter FE, Rglin L, Beil W, Seitz O, et al. Proximicins A, B,
and Cantitumor furan analogues of netropsin from the marine actinomycete
Verrucosispora induce upregulation of p53 and the cyclin kinase inhibitor p21.
Angew Chem Int Ed 2008;47(17):325861.
Schultz AW, Oh D-C, Carney JR, Williamson RT, Udwary DW, Jensen PR,
et al. Biosynthesis and structures of cyclomarins and cyclomarazines, prenylated cyclic peptides of marine actinobacterial origin. J Am Chem Soc
2008;130(13):450716.
Schumacher RW, Talmage SC, Miller SA, Sarris KE, Davidson BS, Goldberg A. Isolation
and structure determination of an antimicrobial ester from a marine sedimentderived bacterium. J Nat Prod 2003;66(9):12913.
Shi C, Zhu Y, Ran X, Wang M, Su Y, Cheng T. Therapeutic potential of chitosan and
its derivatives in regenerative medicine. J Surg Res 2006;133(2):18592.
Shin HJ, Kim TS, Lee H-S, Park JY, Choi I-K, Kwon HJ. Streptopyrrolidine, an
angiogenesis inhibitor from a marine-derived Streptomyces sp. KORDI-3973.
Phytochemistry 2008;69(12):23636.
Shin HJ, Mondol M, Yu TK, Lee H-S, Lee Y-J, Jung HJ, et al. An angiogenesis inhibitor
isolated from a marine-derived actinomycete, Nocardiopsis sp. 03N67. Phytochem Lett 2010;3(4):1947.
Shukla AK, Singh BK, Patra S, Dubey VK. Rational approaches for drug designing
against leishmaniasis. Appl Biochem Biotechnol 2010;160(8):220818.
Smith WC, Xiang L, Shen B. Genetic localization and molecular characterization of
the nonS gene required for macrotetrolide biosynthesis in Streptomyces griseus
DSM40695. Antimicrob Agents Chemother 2000;44(7):180917.
Socha AM, LaPlante KL, Rowley DC. New bisanthraquinone antibiotics and
semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates. Bioorg Med Chem 2006;14(24):
844654.
Soria-Mercado IE, Prieto-Davo A, Jensen PR, Fenical W. Antibiotic terpenoid
chloro-dihydroquinones from a new marine actinomycete. J Nat Prod
2005;68(6):90410.
Stach JEM, Maldonado LA, Ward AC, Goodfellow M, Bull AT. New primers for the
class Actinobacteria: application to marine and terrestrial environments. Environ Microbiol 2003;5(10):82841.
Stritzke K, Schulz S, Laatsch H, Helmke E, Beil W. Novel caprolactones from a marine
streptomycete. J Nat Prod 2004;67(3):395401.
Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need
drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis
2006;42(5):65768.
Tringe SG, Von Mering C, Kobayashi A, Salamov AA, Chen K, Chang HW, et al. Comparative metagenomics of microbial communities. Sci 2005;308(5721):5547.
Urbina JA, Docampo R. Specic chemotherapy of Chagas disease: controversies and
advances. Trends Parasitol 2003;19(11):495501.
Wanner LA. A patchwork of Streptomyces species isolated from potato common scab
lesions in North America. Am J Potato Res 2009;86(4):24764.
Ward AC, Bora N. Diversity and biogeography of marine actinobacteria. Curr Opin
Microbiol 2006;9(3):27986.
Watve MG, Tickoo R, Jog MM, Bhole BD. How many antibiotics are produced by the
genus Streptomyces? Arch Microbiol 2001;176(5):38690.
Weidner N, Carroll P, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143(2):
4019.
Weyland H. Actinomycetes in North Sea and Atlantic Ocean sediments. Nature
1969;223:858.
Williams PG. Panning for chemical gold: marine bacteria as a source of new therapeutics. Trends Biotechnol 2009;27(1):4552.
Williams PG, Miller ED, Asolkar RN, Jensen PR, Fenical W, Arenicolides AC. 26membered ring macrolides from the marine actinomycete Salinispora arenicola.
J Org Chem 2007;72(14):502534.
Williams PG, Buchanan GO, Feling RH, Kauffman CA, Jensen PR, Fenical W. New
cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J
Org Chem 2005;70(16):6196203.
Woolhouse ME. Epidemiology: emerging diseases go global. Nature
2008;451(7181):8989.
Wu SJ, Fotso S, Li F, Qin S, Laatsch H. Amorphane sesquiterpenes from a marine
Streptomyces sp. J Nat Prod 2007;70(2):3046.
Wu SJ, Fotso S, Li F, Qin S, Kelter T, Fiebig HH, et al. 39-N-carboxamidostaurosporine
and selina-4(14),7(11)-diene-8,9-diol, new metabolites from a marine Streptomyces sp. J Antibiot 2006;59:3317.
Wu Z, Xie L, Xia G, Zhang J, Nie Y, Hu J, et al. A new tetrodotoxin-producing actinomycete, Nocardiopsis dassonvillei, isolated from the ovaries of puffer sh Fugu
rubripes. Toxicon 2005;45(7):8519.
Yan J, Li X, Liu L, Wang F, Zhu TW, Zhang Q. Potential use of
collagenchitosanhyaluronan tri-copolymer scaffold for cartilage tissue
engineering. Artif Cells Blood Substitutes Biotechnol 2006;34(1):2739.